A clinical trial of CEN501 a nasal strip product used as a local nasal immunotherapy (LNIT) for the treatment of mite-induced allergic rhinitis patients
Latest Information Update: 10 May 2022
At a glance
- Drugs CEN 501 (Primary)
- Indications Allergic rhinitis
- Focus Adverse reactions
Most Recent Events
- 10 May 2022 New trial record
- 03 May 2022 According to an ABVC Biopharma media release, the company has tested CEN501 in two early clinical trials in Taiwan.